Compare Mesoblast Limited (MESO) vs Global X Defense Tech ETF (SHLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Global X Defense Tech ETF — how do they compare? Mesoblast Limited trades at $16.08 (market cap $2.17B), while Global X Defense Tech ETF trades at $60.3. The key difference: Mesoblast Limited is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals.
| MESO | SHLD | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $20.96 | $78.02 |
52-Week Low | $12.88 | $58.20 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
SHLD trades at $60.03, down 0.05% on the day, with technical indicators showing a bearish trend from moving averages but neutral oscillators. The ETF focuses on global defense technology, benefiting from rising military budgets and geopolitical tensions. Recent news highlights institutional interest, including Decker Wealth Management's new position in Q1 2026, and analyst discussions on defense ETF comparisons amid sector tailwinds.
The outlook for SHLD is supported by structural growth in defense spending, but risks include political uncertainty and valuation concerns. Investors gain diversified exposure to defense tech innovation, though competition from other ETFs and expense ratios may impact relative performance. Near-term price action hinges on technical support at $59 and broader market sentiment toward defense stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →
